SPOTLIGHT: Amgen dodges a bullet


Look on the bright side: It could have been worse. An FDA advisory panel voted to keep Amgen and Johnson & Johnson's anemia remedies on the market for cancer patients. So the drugs appear to have dodged the feared silver bullet, an outright revocation of that indication. FDA generally follows its panels' advice, but isn't required to. FiercePharma